This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Dorbala S, Ando Y, Bokhari S, et al. Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging, Journal of Nuclear Cardiology. 2020; 27 (2): 659–73.Search in Google Scholar
Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2—Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology. 2020; 28(4): 1769–74.Search in Google Scholar
Adam R, Stan C, Onciul S, et al. Amiliodoza cardiacă – o sinteză pentru cardiologii practicieni. StetoscopCardio. 2019, pg12-16.Search in Google Scholar
O'Malley J, Thrall JH, Ziessman H, et al. The Requisites, 5th Edition, Nuclear medicine and molecular imaging, 2021, Elsevier 1600, John F. Kennedy Blvd. Ste 1800 Philadelphia, PA 19103-2899, NUCLEAR MEDICINE AND MOLECULAR IMAGING: THE REQUISITES, 5th EDITION ISBN: 978-0-323-530378.Search in Google Scholar
De Michieli L, Omar F. Ezzeddine A, Abbasi MA, et al. Biomarkers to predict abnormal Technetium-99m Pyrophosphate scans in patients with suspected transthyretin amyloidosis. JACC Cardiooncology 2025; 7 (1): 70-78.Search in Google Scholar
Rettl R, Duca F, Kronberger C, et al. Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging. 2025; 26 (2): 251–260.Search in Google Scholar
Delbarre MA, Chadha GD, Annabi MS, et al. Wild-type transthyretin cardiac amyloidosis and aortic stenosis: Can carpal tunnel syndrome help distinguish the chicken from the egg? J Intern Med. 2025; 297: 186–200.Search in Google Scholar
Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management - A scientific statement from the American Heart Association, American Heart Association. 2020; 142: e7–e22.Search in Google Scholar
Aimo A, Chen YFF, Castiglione V, et al. Positron emission tomography in cardiac amyloidosis: current evidence and future directions. Heart Fail Rev. 2025.Search in Google Scholar
Laptseva N, Benzabc DC, Schwotzerad R, et al. Cardiac amyloidosis. SwissMed Wkly. 2024; 14: 4186.Search in Google Scholar
Wang TKM, Abou Hassan OK, Jaber W, et al. Multimodality imaging of cardiac amyloidosis: Contemporary update. World J Radiol. 2020; 12(6): 87-100.Search in Google Scholar
Sperry BW, Burgett E, Bybee KA, McGhie AI, O'Keefe JH, Saeed IM, et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol. 2020; 27(5): 1802–7.Search in Google Scholar
Castano A, HaqM, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar Technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016; 1(8): 880–9.Search in Google Scholar
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019; 73(22): 2872–2891.Search in Google Scholar
Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, et al. Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis. J AmColl Cardiol Img. 2023; 16(12): 1567–1580.Search in Google Scholar
Ungericht M, Groaz V, Messner M, Schuetz T, Brunelli L, Zaruba MM, et al. Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis. Amyloid. 2024; 31: 22–31.Search in Google Scholar
Löfbacka V, Axelsson J, Pilebro B, Suhr OB, Lindqvist P, Sundström T. Cardiac transthyretin amyloidosis 99mTc- DPD SPECT correlates with strain echocardiography and biomarkers. Eur J Nucl Med Mol Imaging. 2021; 48: 1822–32.Search in Google Scholar
Morioka M, Takashio S, Nakashima N, Nishi M, Fujiyama A, Hirakawa K et al. Correlation between cardiac images, biomarkers, and amyloid load in wild-type transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2022;11:e024717.Search in Google Scholar
Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res.2021; 128(10): 1554–75.Search in Google Scholar
Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. 2020; 27(17): 1806–1815.Search in Google Scholar
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021; 42(16): 1554–1568.Search in Google Scholar
Romero Pabón AJ, Clerc OF, Vijayakumar S, Cuddy SAM, Dorbala S. Recent advances in positron emission tomography radiotracers to image cardiac amyloidosis. Curr Cardiol Rep. 2024; 26(11): 1153–1162.Search in Google Scholar
Rauf MU, Hawkins PN, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J. 2023; 44(24): 2187–98.Search in Google Scholar
Condoluci A, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M, et al. Management of transthyretin amyloidosis. Swiss Med Wkly. 2021; 151(4142): w30053.Search in Google Scholar
